Xponance Inc. Sells 3,083 Shares of Catalent, Inc. (NYSE:CTLT)

Xponance Inc. reduced its stake in Catalent, Inc. (NYSE:CTLT) by 11.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,265 shares of the company’s stock after selling 3,083 shares during the period. Xponance Inc.’s holdings in Catalent were worth $1,045,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Park Place Capital Corp grew its stake in shares of Catalent by 25.2% in the 3rd quarter. Park Place Capital Corp now owns 1,533 shares of the company’s stock worth $70,000 after buying an additional 309 shares in the last quarter. Teacher Retirement System of Texas grew its stake in shares of Catalent by 2.6% in the 3rd quarter. Teacher Retirement System of Texas now owns 13,966 shares of the company’s stock worth $636,000 after buying an additional 350 shares in the last quarter. Arizona State Retirement System grew its stake in shares of Catalent by 0.7% in the 4th quarter. Arizona State Retirement System now owns 49,546 shares of the company’s stock worth $2,226,000 after buying an additional 365 shares in the last quarter. Treasurer of the State of North Carolina grew its stake in shares of Catalent by 0.5% in the 3rd quarter. Treasurer of the State of North Carolina now owns 81,729 shares of the company’s stock worth $3,721,000 after buying an additional 421 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC grew its stake in shares of Catalent by 5.5% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 8,485 shares of the company’s stock worth $386,000 after buying an additional 446 shares in the last quarter.

Catalent Trading Down 0.2 %

NYSE:CTLT opened at $55.92 on Thursday. Catalent, Inc. has a one year low of $31.45 and a one year high of $60.20. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48. The firm has a market cap of $10.12 billion, a P/E ratio of -8.22, a P/E/G ratio of 6.05 and a beta of 1.20. The firm has a 50-day simple moving average of $56.78 and a 200-day simple moving average of $48.48.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the firm posted $0.62 EPS. The company’s revenue for the quarter was down 10.2% compared to the same quarter last year. Equities analysts anticipate that Catalent, Inc. will post 0.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on CTLT shares. UBS Group reissued a “neutral” rating and issued a $63.50 price objective (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. StockNews.com initiated coverage on shares of Catalent in a research note on Friday, April 19th. They set a “sell” rating for the company. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $63.50 price target on shares of Catalent in a research note on Tuesday, February 20th. Stephens reaffirmed an “equal weight” rating and set a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. Finally, Barclays lifted their price target on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Catalent has a consensus rating of “Hold” and an average price target of $52.46.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.